Squaric Acid Dibutyl Ester
Phase 3Small molecule
Squaric Acid Dibutyl Ester is one of 15 small molecule programs targeting Congenital Melanocytic Nevus. It is currently in Phase 3.
2
Indications
4
Total Trials
2
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
14 competitors in Contact Dermatitis
#DrugCompanyPhaseTrials
1Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Rayos
RRoxane Laboratories
Approved
Decadron
AAspen Global Incorporated
Approved
Ilaris
NovartisPhase 3
Tremfya
Johnson & JohnsonPhase 3
Humira
NovartisPhase 3
Stelara
Johnson & JohnsonPhase 3
Flovent
PParatek Pharmaceuticals Inc
Phase 3
Kenalog
BBausch Health Americas, Inc.
Phase 3
Dupixent
AAzienda U.S.L. 1 di Massa e Carrara
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Herpes Labialis1 trial
Contact Dermatitis1 trial
Herpes Simplex Virus1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Squaric Acid Dibutyl Ester. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SSquarex, LLC